NCT06210438尚未招募2 期
SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases：a Prospective, Single-arm, Single-center Phase II Clinical Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- CNS ORR
研究概览
简要总结
This is a phaseⅡ, single-arm study evaluating the efficacy and safety of SHR-A1921 Combined with Bevacizumab in Triple-negative Breast Cancer with Brain Metastases
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years old, both genders
- •ECOG Performance Status of 0-2
- •Pathological tests confirm HR-negative/HER2-negative breast cancer；there is evidence of local recurrence or metastasis；not suitable with curative surgery or radiation therapy；HR negative is defined as: ER-negative and PR-negative, the proportion of positively stained tumor cells in all tumor cells is <10%；HER2- negative is defined as: histologically confirmed to be HER2 IHC (0) or HER2 IHC(1+) or HER2 IHC (2+) and FISH(-)
- •Must have life-expectancy of ≥ 3 months
- •MRI confirmed brain metastases, at least one intracranial parenchymal metastatic lesion with a longest diameter ≥ 1.0 cm without prior radiotherapy；
- •Intraventricular catheter shunting or mannitol、steroid hormone、anticonvulsant drug is allowed before enrollment, but the dose of drug should be stable for at least one week and the neurological symptoms are stable for ≥1 week
- •Adequate function of major organs meets the following requirements (1)Blood routine
- •ANC≥1.5×109/L；
- •PLT≥75×109/L；
- •Hb≥90 g/L(Allows blood transfusion or the use of medication to ensure that the content of hemoglobin) (2)Coagulation
- •INR≤1.5，APTT≤1.5×ULN (3)Blood biochemistry
- •TBIL≤1.5 × ULN;
- •ALT and AST≤3 × ULN (liver metastasis≤5.0 × ULN);
- •Urea nitrogen ≤ 1.5 × ULN; Cr≤1.5 × ULN or creatinine clearance ≥50 mL / min (Cockcroft-Gault formula) (4)Cardiac ultrasound
- •LVEF≥50%; (5)12-lead ECG:
- •females QTcF interval <470msec and males <450ms;
- •Willing to join the study, sign informed consent, have good compliance and cooperate with follow-up.
排除标准
- •Leptomeningeal or cystic metastases confirmed by MRI or lumbar puncture
- •Presence of third interstitial fluid that cannot be controlled by drainage or other methods (e.g., a large amount of pleural effusion and ascites);
- •Whole brain radiotherapy, chemotherapy, biological targeted therapy, immunotherapy, surgery or endocrine therapy within 2 weeks prior to enrolment
- •Has received prior therapy with bevacizumab and TROP-2 ADC drugs
- •Participation in any other clinical trials within 2 weeks of enrollment
- •Concurrent use of any other Anti-cancer drugs
- •Other malignancies within 5 years, except cured in-situ of uterine cervix carcinoma , skin basal cell carcinoma and squamous-cell carcinoma
- •History of heart disease: (1) Arrhythmias requiring medical treatment or clinical significance, (2) Myocardial infarction, (3) Heart failure, (4)Any heart diseases that investigator believes not suitable for this study
- •History of allergy or hypersensitivity to any of the study drugs or study drug components
- •History of immunodeficiency including HIV-positive, active hepatitis B/C, other acquired, congenital immunodeficiency disease or history of organ transplantation
- •A clear history of neurological or mental disorders, including epilepsy or dementia
- •Pregnant or breastfeeding women. Women of childbearing potential who have a positive pregnancy test or unwilling to use adequate contraception prior to enrollment and for the duration of study participation
- •According to the investigator's judgment, there is a concomitant disease that seriously endangers the safety of subjects or affects the completion of the study (including but not limited to severe hypertension, severe diabetes, active infection, thyroid disease that cannot be controlled by drugs)
- •Any condition which in the investigator's opinion makes the subjects unsuitable for the study participation
研究组 & 干预措施
SHR-A1921 + Bevacizumab
Experimental
干预措施: SHR-A1921 + Bevacizumab (Drug)
结局指标
主要结局
CNS ORR
时间窗: from enrollment to progression or death (for any reason), assessed up to 24 months
The proportion of patients who have a CR or PR in the CNS, as determined by the Investigator according to RANO-BM criteria
次要结局
- Safety as assessed by percentage of patients with any Adverse Event(Up to 2 years)
- Overall survival(Up to 2 years)
- First progression site(Up to 2 years)
- CNS CBR(from enrollment to progression or death (for any reason), assessed up to 24 months)
- Progression-free survival(Up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLCAdvanced Non-small Cell Lung CancerNCT06434103Suzhou Suncadia Biopharmaceuticals Co., Ltd.124
尚未招募
3 期
A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-CancerAdvanced or Metastatic Non-squamous Non-small-cell Lung CancerNCT05132413Suzhou Suncadia Biopharmaceuticals Co., Ltd.561
进行中（未招募）
不适用
Phase II study of the combination of Bevacizumab (rhuMab VEGF) plus Capecitabine with pre-operative standard radiotherapy in patients with locally advanced rectal cancer.Patients with locally advanced, non metastatic, resectable primary rectal cancer stage cT3 or cT4 who are subject to combined chemotherapy of the pelvic region in the pre-operative setting.MedDRA version: 14.1Level: PTClassification code 10038038Term: Rectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-000802-30-ITROCHE
已完成
2 期
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 MeningiomaAnaplastic (Malignant) MeningiomaAtypical MeningiomaGrade II MeningiomaGrade III MeningiomaRecurrent MeningiomaSupratentorial MeningiomaNCT02847559Northwestern University20
进行中（未招募）
不适用
Phase II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Oxaliplatin plus Capecitabine (XELOX) in Patients with Advanced Colorectal CancerEUCTR2005-001012-41-ITROCHE